Peer-influenced content. Sources you trust. No registration required. This is HCN.
Eyewire+
“This acquisition immediately advances Biogen’s ongoing transformation… with two approved, best-in-class medicines that complement our existing portfolio.” — Christopher Viehbacher, President and CEO, Biogen
Ophthalmology April 7th 2026
Medical News Today (MNT)
More than 80% of the patients were able to read letters and words, and some of them are reading pages in a book.
Ophthalmology November 25th 2025